Alizapride
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| N-[(1-allylpyrrolidin-2-yl)methyl]-6-methoxy-1H-benzo[d][1,2,3]triazole-5-carboxamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Routes | Oral, IM, IV |
| Pharmacokinetic data | |
| Half-life | 3 hours |
| Excretion | Renal |
| Identifiers | |
| CAS number | 59338-93-1 |
| ATC code | A03FA05 |
| PubChem | CID 43008 |
| DrugBank | DB01425 |
| ChemSpider | 39202 |
| UNII | P55703ZRZY |
| KEGG | D07102 |
| ChEMBL | CHEMBL290194 |
| Chemical data | |
| Formula | C16H21N5O2 |
| Mol. mass | 315.37 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.[1]
[edit] See also
Anon., Drugs Future 1981, 6, 11.
[edit] References
|
|
| This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |

